Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis

Rod S Taylor,^{1,2}* Sarah Walker,¹ Oriana Ciani,^{1,3} Fiona Warren,¹ Neil A Smart,⁴ Massimo Piepoli⁵ and Constantinos H Davos⁶

¹Institute of Health Research, University of Exeter Medical School, Exeter, UK
²Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
³Centre for Research on Health and Social Care Management, Bocconi University, Milan, Italy
⁴School of Science and Technology, University of New England, Armidale, NSW, Australia
⁵Heart Failure Unit, Cardiology, Guglielmo da Saliceto Hospital, Piacenza, Italy
⁶Biomedical Research Foundation, Academy of Athens, Athens, Greece

*Corresponding author r.taylor@exeter.ac.uk

Declared competing interests of authors: Rod S Taylor is currently co-chief investigator on a National Institute for Health Research (NIHR)-funded programme grant designing and evaluating the clinical effectiveness and cost-effectiveness of a home-based cardiac rehabilitation intervention for patients who have experienced heart failure (RP-PG-1210-12004). He is also a member of the NIHR Priority Research Advisory Methodology Group (August 2015–present). Previous roles include the NIHR South West Research for Patient Benefit Committee South West (2010–14); core group of methodological experts for the NIHR Programme Grants for Applied Research programme (2013–October 2017); NIHR Health Technology Assessment (HTA) Themed Call Board (2012–14); NIHR HTA General Board (2014–June 2017); and chairperson of the NIHR Health Services and Delivery Research Researcher-led Panel (March 2014–February 2018).

Published May 2019 DOI: 10.3310/hta23250

Scientific summary

The EXTRAMATCH II individual participant data meta-analysis Health Technology Assessment 2019; Vol. 23: No. 25 DOI: 10.3310/hta23250

NIHR Journals Library www.journalslibrary.nihr.ac.uk

Scientific summary

Background

People with symptomatic heart failure (HF) are living for longer following the onset of their condition, increasing the importance of effective and accessible services for these patients. Exercise-based cardiac rehabilitation (ExCR) is recognised as integral to the comprehensive care of HF patients. ExCR is a process by which patients, in partnership with health professionals, are encouraged and supported to achieve and maintain optimal physical health. Current national [National Institute for Health and Care Excellence. Chronic Heart Failure in Adults: Management. Clinical Guideline [CG108]. URL: www.nice.org.uk/guidance/CG108 (accessed 25 June 2018)] and international [Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240–327; Working Group on Cardiac Rehabilitation; Exercise Physiology and Working Group on Heart Failure of the European Society of Cardiology. Recommendations for exercise training in chronic heart failure patients. Eur Heart J 2001;22:125–35; and McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787–847] guidelines on the management of HF recommend ExCR, but do not differentiate according to patient subgroups.

Objectives

The Exercise Training Meta-Analysis of Trials for Chronic Heart Failure (ExTraMATCH/ExTraMATCH II) project aimed to determine which HF patient subgroups benefit most from ExCR using individual participant data (IPD) meta-analysis.

The project had three objectives:

- To obtain definitive estimates of the impact of ExCR interventions compared with no exercise intervention (control) on mortality, hospitalisation, exercise capacity and health-related quality of life (HRQoL) in HF patients.
- 2. To determine the differential (subgroup) effects of ExCR in HF patients according to their:
 - age
 - sex
 - left ventricular ejection fraction
 - HF aetiology
 - New York Heart Association (NYHA) class
 - baseline exercise capacity.
- 3. To assess whether or not the change in patient exercise capacity mediates, and is an acceptable surrogate end point for, the impact of ExCR on final outcomes of mortality, hospitalisation and HRQoL.

The information gained from the ExTraMATCH II project will inform future UK and international clinical and policy decision-making on the use of ExCR in HF.

Methods

This study was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) IPD statement. Randomised controlled trials were identified from the original ExTraMATCH IPD meta-analysis [Piepoli MF, Davos C, Francis DP, Coats AJ, ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328:189] and the 2014 Cochrane systematic review of ExCR for HF (Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev 2014;4:CD003331). ExTraMATCH and the Cochrane systematic review were based on searches of the following electronic databases: Cochrane Central Register of Controlled Trials in The Cochrane Library, EMBASE, MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), PsycINFO and the NHS Centre for Reviews and Dissemination. Conference proceedings and trial registers were also searched. In keeping with the original ExTraMATCH IPD meta-analysis, trials of exercise training (for at least 3 weeks) compared with no exercise control with \geq 6 months' follow-up were included if they provided IPD on all-cause or HF-specific mortality, hospitalisation, exercise capacity or HRQoL. The data sets of IPD were combined into a single data set. One-stage fixed-effect meta-analyses of time-to-event end points were performed using Cox proportional hazards models, stratified by study. One-stage meta-analyses of continuous outcomes were performed using hierarchical linear models with adjustments for baseline values and a random effect on study. Two-stage models using fixed and random effects were also performed. Interaction terms between ExCR and participant characteristics were used to assess potential differential effects of ExCR across subgroups. Mediational analyses and meta-analytic regressions, with estimation of R^2 at the trial level, and surrogate threshold effect (STE), were performed to assess the question of surrogate validity for exercise capacity outcomes of peak oxygen uptake (VO_2 peak) and the 6-minute walk test (6MWT).

Results

Of the 23 eligible trials (4398 patients), 19 trials contributed data to the IPD meta-analysis [18 trials (3912 patients) to the clinical events (mortality and hospitalisation) analysis, 13 trials (3332 patients) to exercise capacity and HRQoL analysis, and 10 trials (2656 patients) to the exercise capacity mediational/ surrogate end-point analysis].

Characteristics and quality of included trials

Patient characteristics at baseline were well balanced between ExCR and control group patients. The majority of patients were male (74%), had a mean age of 61 years, had experienced heart failure with reduced ejection fraction (HFrEF) (mean baseline left ventricular ejection fraction 26.7%), and most patients were in NYHA functional class II (59%) or III (37%). No included trials recruited patients with HF with a preserved ejection fraction of > 45%. Trials were conducted in Europe and North America and were published between 1990 and 2012, and the sample sizes ranged from 50 to 2130 patients. All trials evaluated an aerobic exercise intervention, which was most commonly delivered in either an exclusively centre-based setting or a centre-based setting in combination with some home exercise sessions. The dose of exercise training ranged widely across trials. ExCR was delivered over a period of 12–90 weeks, with between two and seven sessions per week (median session duration was between 15 and 120 minutes, including warm-up and cool-down). The intensity of exercise ranged between 50% and 85% *V*O₂peak. The overall quality of included trials was measured using the Tool for the assEssment of Study qualiTy and reporting in EXercise (TESTEX), a measure of study quality and reporting. Most studies were judged as being moderate to good, with a median TESTEX score of 11 (range 9–14) out of a maximum score of 15.

Impact of ExCR on mortality and hospitalisation

Compared with control, there was no statistically significant difference in pooled time-to-event estimates in favour of ExCR, although confidence intervals (CIs) were wide: all-cause mortality had a hazard ratio (HR) of 0.83 (95% CI 0.67 to 1.04); HF-related mortality had a HR of 0.84 (95% CI 0.49 to 1.46); all-cause

© Queen's Printer and Controller of HMSO 2019. This work was produced by Taylor *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

hospitalisation had a HR of 0.90 (95% CI 0.76 to 1.06); and HF-related hospitalisation had a HR of 0.98 (95% CI 0.72 to 1.35). No strong evidence for differential intervention effects across patient characteristics was found.

Impact of ExCR on exercise capacity and health-related quality of life

Compared with the control, there was a statistically significant difference in favour of ExCR for exercise capacity and HRQoL. For example, at 12 months' follow-up, improvements were seen in the 6MWT (mean 21.0 m, 95% CI 1.57 to 40.4 m; p = 0.034, $\tau^2 = 491$, $l^2 = 78\%$) and the Minnesota Living with Heart Failure Questionnaire score (mean –5.94, 95% CI –1.0 to –10.9; p = 0.018, $\tau^2 = 77$, $l^2 = 88\%$); lower scores indicate improved HRQoL. No strong evidence for differential intervention effects across patient characteristics was found.

Validation of exercise capacity as a surrogate end point

Moderate to good levels of correlation ($R^2_{trial} > 50\%$ and p > 0.50) between exercise capacity VO_2 peak or 6MWT with mortality and HRQoL were seen. Estimated STE was an increase of 1.6 to 4.6 ml/kg/minute for VO_2 peak. The results indicate that an increase in VO_2 peak or an improvement in the 6MWT with ExCR is a potentially weak mediator of final outcomes.

Discussion

In HFrEF patients, ExCR did not have a statistically significant effect on the risk of mortality and hospitalisation. However, uncertainty around effect estimates and lack of IPD on exercise adherence precludes drawing definitive conclusions in these event outcomes. ExCR significantly improves exercise capacity and HRQoL. No consistent differences were found in ExCR effects across patient subgroups. The results provide indicative evidence that *V*O₂peak and the 6MWT may be suitable surrogate end points for the treatment effect of ExCR on final outcomes in HF.

Recommendations for further research

Two central aspects of future data collection are (1) a consensus on the definition, collection and reporting of core sets of outcome data, concomitant disease/comorbidities and metrics of therapy delivery/uptake; and (2) the capture of data on patient-level adherence to the amount of exercise training during the ExCR intervention period. More generally, the research community should continue to implement policies that encourage primary study authors to make their data sets available, by either depositing in publicly available repositories or sharing with IPD meta-analysis collaborations when directly requested.

Study registration

This study is registered as PROSPERO CRD42014007170.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 4.513

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 15/80/30. The contractual start date was in November 2016. The draft report began editorial review in July 2018 and was accepted for publication in February 2019. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2019. This work was produced by Taylor *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

NIHR Journals Library Editor-in-Chief

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Honorary Professor, University of Manchester, and Senior Clinical Researcher and Associate Professor, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

Professor Matthias Beck Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont Director, NIHR Dissemination Centre, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk